Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology Inc. presents a promising outlook due to its advanced stage in clinical trials for cretostimogene grenadenorepvec, specifically addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). The potential for strong market positioning stems from the candidate's differentiated efficacy and durability, which are likely to enhance clinical adoption as it meets the significant unmet need for next-generation therapies that improve patient quality of life and resource efficiency. Additionally, the anticipated expansion into previously untreated populations, alongside projected peak revenues of approximately $1.0 billion for high-risk BCG-unresponsive NMIBC, underscores a substantial market opportunity supporting a positive long-term financial outlook for the company.

Bears say

The potential for CG Oncology's stock to perform poorly is primarily driven by several fundamental concerns regarding its lead product candidate, cretostimogene grenadenorepvec. A hazard ratio below 0.7 or a recurrence-free survival rate below 75% could significantly limit its market adoption, thereby undermining the company's expansion plans in treating intermediate-risk non-muscle invasive bladder cancer (NMIBC). Additionally, reliance on regulatory approvals presents a risk; any delays or negative trial outcomes could stifle commercialization efforts and diminish investor confidence.

CGON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 10 analysts, CGON has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.